NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Florida State University
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Adherence
Interventions: Improving Cognitive Aging through Nutrition (ICAN) Adherence Program, Improving Cognitive Aging through Nutrition, Mediterranean diet
Countries: United States
Objective 1: To scale-up the nutrition adherence intervention for testing in racially diverse rural communities in North Florida. The investigators hypothesize that: 1\. The protocol will produce at least 75% of participants obtaining measurable levels of urine ketones (e.g., good adherence) in the Modified Mediterranean-Ketogenic diet (MMKD) group and an average score of \>6 on the MEDAS questionnaire in the Mediterranean group during the 10-week program. Further, we hypothesize that the use of ongoing monthly support groups will bolster long-term adherence. Objective 2: To evaluate the effects of adherence to Mediterranean versus MMKD on novel gut-brain axis markers of Alzheimer's disease pathogenesis in individuals with mild cognitive impairment compared to cognitively normal older adults. The investigators hypothesize that individuals with mild cognitive impairment will: 1. Have greater evidence of gut dysbiosis at baseline than cognitively normal controls and 2. Will demonstrate greater increases in beneficial gut microbial metabolites in response to adherence to Mediterranean-Ketogenic nutrition and the Mediterranean diet compared to CN controls.
Sex: ALL
Age: 55 Years to 85 Years
Healthy volunteers: Yes
Study type: INTERVENTIONAL
Inclusion Criteria: * Ages 55-85 * converted telephone MoCA total score: MCI = 17 ≤ 26, CN= ≥27 and/or and/or MCS MCI≥3, CN\<3 * interest in participating in a nutrition program * stable medical condition (at least 3 months prior to screening visit) at the discretion of study physician * stable on medications if any (at least 4 weeks prior to screening visit) at the discretion of study physician * able to complete the required assessments Exclusion Criteria: * MoCA ≤ 16, or diagnosis of neurodegenerative illness (except MCI or early AD in the MCI group) * current evidence or history in the last 1 year of focal brain lesion, head injury with loss of consciousness, or any major psychiatric disorder including psychosis, bipolar disorder, severe major depression (PHQ-9 \> 20), alcohol or substance abuse, or disordered eating symptoms (SCOFF \> 2) * sensory impairment (visual or auditory) that might preclude participant from participating in the study * serious medical risk or organ failure, such as type 1 diabetes mellitus, recent cardiac event (e.g. heart attack, angioplasty) * prescribed Warfarin, insulin, or immunosuppressants * use of medications including anticonvulsants, drugs with potential interfering CNS effects (except cholinesterase inhibitors or memantine), and medications with known anticholinergic activity * a nut or fish allergy (does not include shellfish) * current use of highly restrictive or specialized diet regimen (e.g., vegan, use of MAOIs etc.) * major digestive disorders, absorption issues, or surgeries that could be exacerbated by dietary intervention * Non-English speaking.
- Tallahassee, Florida, United States